using a linear gradient of 5-50% buffer B (90% CH 3 CN: 10% Buffer A -0.1% trifluoroacetic acid (TFA) in H 2 O) over 25 min. The flow rate was 1.0 ml/min and UV was monitored at 214 nm. Pure Bc-III was obtained by means of repurification using the same column under 28% B isocratic conditions and at a higher flow rate (1.2 ml/min). The Bc-III and AFT-II mass spectra were obtained using a Q-Tof mass spectrometer (Micromass, UK) in Qq-orthogonal time-of-flight configuration. An Ettan Maldi-Tof / Pro mass spectrometer (Amersham Biosciences) was also used with -cyano-4-hydroxycinnamic acid as the matrix. Both machines were operated in positive mode. The amino acid sequence of Bc-III was confirmed by means of N-terminal determination using automatic Edman degradation and a PPSQ/230 gas-phase sequencer (Shimadzu Corp., Tokyo, Japan). A search for peptide homology/similarity and multiple sequence alignment were performed using the BLAST (www.ncbi.nlm.nih.gov) and Swiss-Prot databases (www.expasy.ch/sprot/sprot-top.html). The accession numbers are P01528 for ATX-II, P10454 for AFT-II, and A37435 for Bc-III.
ATX-II was obtained from Sigma (Italy) and AFT-II was a kind gift from Dr. Koji Muramoto 4 of the Department of Biological Science at Tohoku University (Japan). All of the chemicals were of the highest purity available and double-distilled water was used throughout.
LD 50 determination. The 50% lethal dose (LD 50 ) of Bc-III was determined intraperitoneally (i.p.) using white balb-C mice (Mus musculus) according to Meier and Theakston (1986) 7 .
Electrophysiology
Cell culture. HEK293 cell lines stably expressing human Na v 1.1, 1.2, 1.3, 1.5 and 1.6 (cultured in modified Dulbecco's medium supplemented with 10% fetal bovine serum) were obtained by transfection with the corresponding pCIN5 expression vector 8 and selection of G418 resistant clones.
pCIN5-hNa V 1.3, and 1.6 were generated as previously described 9, 10 . pCIN5-hNa V 1.2 was generated cDNA libraries, and pCIN5-hNa V 1.5 was generated using a human Na V 1.5 cDNA assembled from partial clones isolated from a cDNA library made from human heart (Clare, J.J., unpublished). Na v 1.4 expressing cells were obtained after transient transfection of a plasmid containing the hNa v 1.4 construct (a kind gift from Prof. Diana Conti-Camerino, University of Bari, Italy). Known quantities of the toxins were dissolved in the extracellular solution immediately before the experiments. When contaminating potassium currents were seen, tetrodotoxin (TTX, Sigma, Italy) was used at 100 nM (on Na v 1.1, 1.2, 1.3, 1.4 and 1.6 currents) and the resulting traces were subtracted from control traces to obtain the TTX-sensitive currents. The Na v 1.5 clone (which has a TTX ID 50 much higher than 100 nM) never showed significant potassium currents at the test potentials. The extracellular solutions were delivered through a 9-hole (0.6-mm) remote-controlled linear positioner with an average response time of 2-3 seconds that was placed near the cell under study.
Solutions and drugs.

Patch-clamp recordings and data analysis.
The currents were recorded at room temperature by means of the MultiClamp 700A (Axon Instruments, USA) as previously described 12 with a pipette resistance of about 1.5-2.2 M cell capacitance and series resistance errors were carefully compensated for (85-90%) before each voltage clamp protocol run in order to reduce the voltage errors to less than 5% of the protocol pulse. The P/N leak procedure was routinely used. Voltagedependent steady-state inactivation was determined by means of a double-pulse protocol in which a conditioning pulse was applied from a holding potential of -80 mV to a range of potentials from -110
(or -130) to -10 (or -30) in 10 or 15 mV increments for 450 msec, immediately followed by a test pulse to -10 (or -20) mV. The peak current amplitudes during the tests were normalised to the amplitude of the first pulse and plotted against the potential of the conditioning pulse. The data were fitted using two exponential terms and a constant value beginning at the current peak. When necessary, the time constant of the fast inactivating term was fixed to the average fast time constant obtained in control curves. Recovery from inactivation was determined using a three pulse protocols, which began with conditioning depolarisation from a holding potential of -120 mV to -10 (or -20) mV for 60 (or 100) msec which inactivated >95% of the channels. This was followed by an increasing recovery time interval at -80 mV and a test depolarisation to -10 (or -20) mV. The time intervals in successive episodes were 2, 5, 10, 20, 50 msec (but see the specific fugure legends). pClamp 8.2
(Axon Instruments, U.S.A.) and Origin 7 (Microcal Inc, USA) software were routinely used during data acquisition and analysis.
RESULTS
Bc-III and AFT-II purification, amino acid sequence and LD 50
Gel filtration chromatography of B. caissarum venom yielded six main peaks (I-VI). Peak IIIa (Fig. 1A) had the greatest neurotoxicity and was further purified by RP-HPLC steps leading to the pure toxin Bc-III (Fig. 1B) . Mass spectrometry analysis showed that the molecular mass of Bc-III was 4.976 atomic mass units (amu) (4.973 5 ) , and the determination of twenty-five N terminal amino acid residues (gvacrcdsdgptsrgntltgtlwlt) by automated Edman degradation confirmed the identity of the major toxin Bc-III (Table 1) reported by Malpezzi et al. 5 . The high purity of AFT-II was determined by mass spectrometry and its molecular mass was also confirmed (4.941 amu). The intraperitoneal LD 50 of Bc-III in mice was 600 g/kg, very similar to that reported for AFT II (450 g/kg) 13 .
Fig. 1 and Table 1 near here Basic properties of biophysical effects of ATX-II on Na v 1.5 and data analysis
As explained in Methods, all of the experiments were performed at fixed drug concentrations using the currents elicited before and during drug perfusion (for 25-40 sec) at successively increasing concentrations. Recovery was always checked after the experiment.
It is well known that the main action of sea anemone neurotoxins is to slow the inactivation process. We therefore mainly used protocols (double pulse, see inset to Fig. 2A ) capable of deriving these properties and compared traces at the same test potential under control conditions and during toxin perfusion. The action of ATX-II on the Na v 1.5 channel was the starting point used to establish the protocols for recording the data and analysing the results. Observation of the action of increasing toxin concentrations clearly showed in first approximation that the drug is in equilibrium at a fixed concentration, with a fraction of the total number of channels on each cell. We checked this result several times and consequently analysed the data on the assumption that each Na + current trace is the sum of two exponential decaying components and a steady-state component. Under control conditions, the amplitude of the fast component was generally large and the other two components were normally very low or negligible. During toxin action, there was a large increase in the slow component and in some cases (depending on the toxin type) an additional increase in a persistent component. We also systematically observed that the quality of fitting of the toxin-induced currents was not different if we used a free or fixed (control value) fast time constant. This strongly suggests that the currents recorded in the presence of the toxin were always the sum of two types of currents:
those deriving from toxin-bound channels (modified) and those deriving from toxin-free channels (not modified and thus equivalent to control channels). This is shown in Fig was dissected into a fast ( ) and slow component ( ). The relative increase and decrease in these components is plotted in Fig. 2E for different concentrations (n=4), which shows that the contribution of bound and unbound channels consistently changes in relation to the toxin concentration.
FIG. 2 near here
Following this finding, we investigated the recovery from inactivation at -80 mV (see protocol below The results of experiments on cells expressing the Na v 1.1 channel are shown in Figure 4 . In the nine panels, the data are divided in three columns for ATX-II (n=3), AFT-II (n=4) and Bc-III (n=4).
The first row ( The results of experiments similar to those reported for Na v 1.1 are shown in Fig. 5 for Na v 1.2 channels. Once again, the action of ATX-II (n=3) was seen at much lower concentrations than those of AFT-II and Bc-III (n=4). Although at high concentrations ATX-II and Bc-III often led to a slight increase in peak currents with respect to control, the effect of AFT-II on peak currents was more marked (increase of the order of 60 ± 5.4% (n=3)), and in addition a large persistent component was induced that was not inactivated at -20 mV (insets to Fig. 5H ).
FIG.5 near here The effects of ATX-II, AFT-II and Bc-III on Na v 1.3.
Similar experiments were also performed for the Na v 1.3 channel (see Fig. 6 ). The three toxins
were effective only at relatively higher concentrations. As noted for Na v 1.2, only AFT-II induced a large increase in peak current (see insets to Only ATX-II led to a negatively shifted inactivation curve of the slow component.
FIG. 6 near here The effects of ATX-II, AFT-II and Bc-III on Na v 1.4.
The effect of the three toxins on the Na v 1.4 channel are shown in Figure 7 . The inactivation time constant under control conditions was 0.5 ± 0.15 ms (n=7), but this increased about ten fold following application of the toxins. Nevertheless, the slow component time constants for Na v 1.4 are the lowest among the subtypes tested (see Table 2 ). It is worth noting that both ATX-II and AFT-II induced a non-parallel leftward shift of the inactivation curve that was more pronounced towards the most negative region, and that the recordings were devoid of any persistent component. Only Bc-III generated a small steady-state component.
FIG. 7 near here The effects of ATX-II, AFT-II and Bc-III on Na v 1.6.
Unlike those observed for the Na v 1.5 channels, the results obtained for Na v 1.6 channels (see 
FIG. 8 near here Comparative effects of the inactivation process on the whole Na v series
In general (with the exception of Na v 1.5), the time constants of the toxin-induced slow inactivation component did not vary as a function of toxin concentration (see first three columns of Table 2 ). It can be seen that Bc-III produced the relatively highest time constant values, but Na v 1.4 is an exception and Na v 1.2 was affected to the same extent by all three toxins.
The same table also shows the shifts (on the voltage axis) of the voltage-dependent inactivation curves for both the slow and the steady-state component. The shift of the slow component was almost always negative (with the exception of Bc-III on Na v 1.1), whereas the shifts of the SS component were always positive; note that Na v 1.6 was greatly affected by the three toxins. In order to quantify and compare the effects of the three toxins on the various Na + channels,
we evaluated the amplitude of the slow and steady-state toxin-induced components in relation to drug concentrations. All of the data were corrected for the amplitude of the slow component in the control recordings (normally less than 7-8%), and normalised to the control peak amplitude in each cell. The resulting dose-response curves (ATX-II , AFT-II , Bc-III ) are shown in Figure 9 . We were sometimes unable to reach the maximal effect when the toxin potency was too low because there was insufficient experimental material. Steady-state components were not observed with some subtypes, and the fact that this always led to a marked rightward shift of the inactivation curves suggests this is probably due to changes in the biophysics of the channel as a result of binding to sites other than those responsible for slowing the inactivation. Simple visual inspection indicated that some dose-response curves were not sufficiently good to fit the classical logistic equation reasonably, and so only an approximate EC 50 is given; for all of the other data, the results of the fitting procedure are shown in Tables 3A for the slow and 3B for the steady-state components.
As shown in table 3A, ATX-II is highly potent at Na v 1.1 and Na v 1.2 with an EC 50 of about 7 nM (n=6). In contrast AFT-II, which is only a single amino acid different, has only weak efficacy for these subtypes and has greatest efficacy for Na v 1.4 and Na v 1.5 (EC 50 of about 30 and 62 nM respectively). AFT-II and ATX-II had similar efficacies at both Na v 1.5 (about 55 nM) and at Na v 1.6
(about 240 nM). Bc-III has the lowest efficacy of all the toxins with the greatest effects being on Na v 1.1 and Na v 1.5 (EC 50 values of aroundt 300 nM).
In conclusion, the following EC 50 rank order was found:
ATX-II, Na v 1.1 ~ Na v 1.2 << Na v 1.5 < Na v 1.4 < Na v 1.6 < Na v 1.3
AFT-II, Na v 1.4 < Na v 1.5 < Na v 1.6 < Na v 1.3 ~ Na v 1.1 < Na v 1.2
Bc-III, Na v 1.5 ~ Na v 1.1 < Na v 1.4 ~ Na v 1.6 < Na v 1.2 ~ Na v 1.3
The greatest efficacy (measured as the increase in the slow component) was obtained by AFT-II in the Na v 1. Previous studies 3 of ATX-II have suggested that it is more specific for cardiac than skeletal muscle or brain voltage-gated Na + channels, but no specific gene was known at that time. ATX-II prolongs the duration of the cardiac action potential by increasing the functional contribution of the Na + current to the plateau 14 , and has been used by a number of authors to investigate its ability to enhance persistent sodium currents 15, 16 .
Detailed electrophysiological analyses of the different effects of sea anemone peptides on sodium channels have been reported 17, 18, 19 , and various criteria have been used to produce comparative dose-response curves: some authors have evaluated the increase in the amplitude of the toxin-induced slow component, and others the value of the current after the completion of fast inactivation, or the increase in the inactivation time constant. As there is evidence indicating the coexistence of toxin-bound and toxin-free channels, we used the first criterion for both the toxin-induced slow and persistent components 20 (see Results).
The changes in Na + channel kinetics induced by Bc-III and AFT-II have never been analysed before, and we compared their effects on six Na + channel subtypes. These have highly related but differing aa sequences, such that differences in the effects of any given toxin should be directly due to these sequence variations. In considering this it should also be remembered that the -subunit of Na + channels is normally complexed with -subunits, though it has been shown that overexpression of the 1 subunit in CHO-expressing -subunits does not alter the inactivation time constant 21 . Moreover, it is known that 1A subunit mRNA is endogenously expressed in HEK293 cells (used in this study) 22 .
However, in our experiments we did not investigate the effect of beta subunits.
Different potencies of the same toxin caused by the amino acid diversity of Na + channels at the IV S3-S4 loop domain
The results of site-directed mutagenesis studies have suggested that sea anemone toxins (and the -toxins purified from scorpions that induce similar actions) interact with a glutamic acid residue (E1613 in Na v 1.2) on the extracellular S3-S4 loop of the fourth domain of the rat neuronal channel Nav1.2 (see Table 4 ) 23 . Table 4 shows that this aa has an aspartic change in cardiac, muscle and other channels (Na v 1.5, Na v 1.4, Na v 1.6, Na v 1.7 ). Furthermore, E1616 also has a change in glutamine in Na v 1.4 and Na v 1.5. The authors found that the E1613D mutation significantly increased the affinity of ATX-II from 76 to 13 nM, and that the E1616Q mutation had the opposite effect (from 76 to 163 nM).
Unfortunately, they did not show the results of both mutations but suggest that the conversion of E1613 or E1616 to more negative/positive side chains respectively increased/decreased ATX-II affinity, and thus proposed a model for electrostatic interaction between the acidic residues of the channel and the basic residues of the toxin.
As these changes occur simultaneously in Na v 1.4 and Na v 1.5, our EC 50 data of 109 and 49 nM in Na v 1.4 and Na v 1.5, in comparison with ~7 nM in Na v 1.2, suggest that decreasing affinity is the prevalent effect.
Unexpectedly, Na v 1.6 (which has only the first glutamate changed in aspartate in position 1604) also had no higher affinity for ATX-II. This channel is much more similar to Na v 1.1-2 because it has the single DI motif (also in Na v 1.5) instead of EL motif present in Na v 1.1-2, thus suggesting a further determinant of toxin binding. Interestingly, Na v 1.4, which is less affected by ATX-II than Na v 1.5, has the DL instead of the DI motif, but the leucine is exactly the same aa as that in Na v 1.1/2.
In comparison with Na v 1.1/2, the much lower potency of ATX-II in Na v 1.3 may be explained by the fact that neighbouring aas can negatively manipulate the binding. The single change of a leucine to a methionine residue is precisely near E1608 (in Na v 1.3), which is consistent with the idea that a longer side chain (Met instead of Leu) should induce a lower affinity for ATX-II 23 .
AFT-II mainly affects the Na v 1.4 and Na v 1.5 channels, and has much less potent effects on the other channels. Given the single aa difference (K36A) between ATX-II and AFT-II, these findings strongly support the idea that the lysine in position 36 is crucial for the very strong effects of ATX-II on Na v 1.1/2 channels.
Bc-III has a different aa sequence from that of ATX-II and AFT-II (see Table 1 ) in both the critical positions of 12-14 and 35-37, which probably explains why it is less effective than ATX-II.
It is very interesting that a previous report 24 27, 28 , but it has more recently been shown by Benzinger et al. 29 that the Lys-37 position of ApB interacts with the D1610 of Na v 1.5 (corresponding to the E1613 of Na v 1.2). They specifically found that the change D1610R causes a 100-fold increase in toxin K D . Moreover, a toxin mutation (K37A) caused a 10-fold K D increase in WT channel and a much smaller increase in the D1610R channel mutant.
In ATX-II and AFT-II, the corresponding Lys is in position 35 and preceded by a wellpreserved structure that is common to all of the toxins. The following aa (position 36) is also a Lys in
ATX-II, but is changed to an Ala in AFT-II (the only difference between the two toxins). AFT-II and
ApB are equal in this region, and our studies may therefore elucidate the importance of this hypothesised toxin-channel interaction.
We found that AFT-II and ATX-II are equally potent on Na v 1.5 (EC 50 about 55 nM), in reasonable agreement with Benzinger's ApB affinity data and the hypothesis of the crucial role of Lys 37. On the contrary, it is not at all confirmed in Na v 1.1/2/3, because ATX-II is much more potent than AFT-II on the first two channels but less potent than AFT-II on Na v 1.3. As the only difference between the two toxins is the K36A mutation, and Na v 1.1 and Na v 1.2 are also identical in that region, it is necessary to attribute a crucial function to Lys36 at least in Na v 1.1/2 and not to Lys35. This suggests that the neighbouring aas of the toxin may be critical for the binding. Although previous observations and Benzinger's data seem to confirm the importance of Asp1610 in Na v 1.5, the same aa is also present in Na v 1.6 (followed by an Ile as in Na v 1.5), but AFT-II and ATX-II are about five times less potent in this channel type. On the other hand, the previous aa in Na v 1.5 is a polar Ser instead of the aliphatic Ala present in all of the other channels. We are therefore again forced to conclude that adjacent aas should be crucial, as it is confirmed by the dose-response data in Na v 1.4, which is much more similar to Na v 1.5 than to Na v 1.6.
During our experiments, we found that the toxins only sometimes induce a prominent steadystate component, which has a pronounced right-shifted inactivation characterised by a persistent component at potentials of about -30/-20 mV. In relation to this, two effects can be distinguished:
toxins are especially strong on this aspect and channels are especially prone to be affected in this way.
AFT-II was capable of causing this effect to a large extent, and Na v 1.3 and Na v 1.6 responded with a large steady-state component. This suggests that the aa pattern in region 35-36 of the toxin can cause a supplementary alteration that leads to the persistent component.
The fact that ATX-II is less potent in inducing slow inactivation in Na v 1.3 than AFT-II may be related to its ability to produce the persistent component in Na v 1.3. On the whole, both effects should suggest an alternative explanation: the toxins do not bind the Na v 1.3 channel in the same position (Glu) as ATX-II does in Na v 1.1 and Na v 1.2.
Concluding remarks
Billions of years of evolution have randomly led to the existence of family of closely related mammalian sodium channel subtypes and to the selection of an array of peptide toxins, produced by predatory animals, that exert their effects upon these channels. The study of these natural variants is a complementary approach to site-directed mutagenesis that will help define their mutual interactions and should lead to an understanding of the structure, function and mechanism of action of both the channels and the toxins themselves.
The present study is restricted to the effects of the toxins on recombinant Na V channel subtypes: i.e. a prolongation and increase of the currents was observed. The physiological consequences of this gain-of-function effect with respect to neuronal firing properties, propagation and contraction of skeletal muscle cells and cardiac action potential duration remain to be determined if we are to fully understand the functional impact of these toxins .
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ATX-II -G V P C L C D S D G P S V R G N T L S G I I W L --A G C P S G W H N C K K H G P T I G W C C K Q AFT-II G G V P C L C D S D G P S V R G N T L S G I I W L --A G C P S G W H N C K A H G P T I G W C C K Q AP-C -G V P C L C D S D G P S V R G N T L S G I L W L --A G C P S G W H N C K A H G P T I G W C C K Q AP-B -G V P C L C D S D G P R P R G N T L S G I L W F Y P S G C P S G W H N C K A H G P N I G W C C K K BcIII -G V A C R C D S D G P T S R G N T L T G T L W L T -G G C P S G W H N C R G S G P F I G Y C C K K BgII -G A S C R C D S D G P T S R G N T L T G T L W L I -G R C P S G W H N C R G S G P F I G Y C C K Q BgIII -G A S C R C D S D G P T S R G D T L T G T L W L I -G R C P S G W H N C R G S G P F I G Y C C K Q ATX-I -G A A C L C K S D G P N T R G N S M S G T I W V F --G C P S G W N N C E G R -A I I G Y C C K Q ATX-II -G G V V P P C C L L C C D D S S D D G G P P S S V V R R G G N N T T L L S S G G I I I I W W L L --A A G G C C P P S S G G W W H H N N C C K K K H H G G P P T I I G G W W C C C C K K Q Q AFT-II G G G V V P P C C L L C C D D S S D D G G P P S S V V R R G G N N T T L L S S G G I I I I W W L L --A A G G C C P P S S G G W W H H N N C C K K A A H H G G P P T I I G G W W C C C C K K Q Q AP-C -G G V V P P C C L L C C D D S S D D G G P P S S V R R G G N N T T L L S S G G I I L L W W L L --A A G G C C P P S S G G W W H H N N C C K K A A H H G G P P T I I G G W W C C C C K K Q Q AP-B -G G V V P P C C L L C C D D S S D D G G P P R P R R G G N N T T L L S S G G I I L L W W F Y P S G G C C P P S S G G W W H H N N C C K K A A H H G G P P N I I G G W W C C C C K K K BcIII -G G V V A C C R C C D D S S D D G G P P T T S S R R G G N N T T L L T T G G T L L W W L L T -G G G G C C P P S S G G W W H H N N C C R R G G S G G P P F I I G G Y Y C C C C K K K BgII -G G A S C C R C C D D S S D D G G P P T T S S R R G G N N T T L L T T G G T L L W W L L I -G G R C C P P S S G G W W H H N N C C R R G G S G G P P F I I G G Y Y C C C C K K Q Q BgIII -G G A S C C R C C D D S S D D G G P P T T S R R G G D T T L L T T G G T L L W W L L I -G G R C C P P S S G G W W H H N N C C R R G G S G G P P F I I G G Y Y C C C C K K Q Q ATX-I -G G A A C C L L C C K S S D D G G P P N T R R G G N N S S M M S S G G T I I W W V V F --G G C C P P S S G G W W N N N C C E G G R -A I I I G G Y Y C C C C K K Q QATX-II -G V P C L C D S D G P S V R G N T L S G I I W L --A G C P S G W H N C K K H G P T I G W C C K Q AFT-II G G V P C L C D S D G P S V R G N T L S G I I W L --A G C P S G W H N C K A H G P T I G W C C K Q AP-C -G V P C L C D S D G P S V R G N T L S G I L W L --A G C P S G W H N C K A H G P T I G W C C K Q AP-B -G V P C L C D S D G P R P R G N T L S G I L W F Y P S G C P S G W H N C K A H G P N I G W C C K K BcIII -G V A C R C D S D G P T S R G N T L T G T L W L T -G G C P S G W H N C R G S G P F I G Y C C K K BgII -G A S C R C D S D G P T S R G N T L T G T L W L I -G R C P S G W H N C R G S G P F I G Y C C K Q BgIII -G A S C R C D S D G P T S R G D T L T G T L W L I -G R C P S G W H N C R G S G P F I G Y C C K Q ATX-I -G A A C L C K S D G P N T R G N S M S G T I W V F --G C P S G W N N C E G R -A I I G Y C C K Q ATX-II -G G V V P P C C L L C C D D S S D D G G P P S S V V R R G G N N T T L L S S G G I I I I W W L L --A A G G C C P P S S G G W W H H N N C C K K K H H G G P P T I I G G W W C C C C K K Q Q AFT-II G G G V V P P C C L L C C D D S S D D G G P P S S V V R R G G N N T T L L S S G G I I I I W W L L --A A G G C C P P S S G G W W H H N N C C K K A A H H G G P P T I I G G W W C C C C K K Q Q AP-C -G G V V P P C C L L C C D D S S D D G G P P S S V R R G G N N T T L L S S G G I I L L W W L L --A A G G C C P P S S G G W W H H N N C C K K A A H H G G P P T I I G G W W C C C C K K Q Q AP-B -G G V V P P C C L L C C D D S S D D G G P P R P R R G G N N T T L L S S G G I I L L W W F Y P S G G C C P P S S G G W W H H N N C C K K A A H H G G P P N I I G G W W C C C C K K K BcIII -G G V V A C C R C C D D S S D D G G P P T T S S R R G G N N T T L L T T G G T L L W W L L T -G G G G C C P P S S G G W W H H N N C C R R G G S G G P P F I I G G Y Y C C C C K K K BgII -G G A S C C R C C D D S S D D G G P P T T S S R R G G N N T T L L T T G G T L L W W L L I -G G R C C P P S S G G W W H H N N C C R R G G S G G P P F I I G G Y Y C C C C K K Q Q BgIII -G G A S C C R C C D D S S D D G G P P T T S R R G G D T T L L T T G G T L L W W L L I -G G R C C P P S S G G W W H H N N C C R R G G S G G P P F I I G G Y Y C C C C K K Q Q ATX-I -G G A A C C L L C C K S S D D G G P P N T R R G G N N S S M M S S G G T I I W W V V F --G G C C P P S S G G W W N N N C C E G G R -A I I I G G Y Y C C C C K K Q Q ATX-II -G G V V P P C C L L C C D D S S D D G G P P S S V V R R G G N N T T L L S S G G I I I I W W L L --A A G G C C P P S S G G W W H H N N C C K K K H H G G P P T I I G G W W C C C C K K Q Q
AFT-II G G G V V P P C C L L C C D D S S D D G G P P S S V V R R G G N N T T L L S S G G I I I I W W L L --A A G G C C P P S S G G W W H H N N C C K K A A H H G G P P T I I G G W W C C C C K K Q Q
AP-C -G G V V P P C C L L C C D D S S D D G G P P S S V R R G G N N T T L L S S G G I I L L W W L L --A A G G C C P P S S G G W W H H N N C C K K A A H H G G P P T I I G G W W C C C C K K Q Q
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